-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: PDUFA
FDASIA: A Step Forward for Patients
Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >
Empowering You to Make a Difference in Health Care Policy
Access to medicines. Healthcare reform. Innovation. These issues are critical to the health of Americans — and the Campaign for Modern Medicines is working on them every day. The Campaign for Modern Medicines is a coalition of non-profit organizations, businesses, and individuals from across the country who believe that a vibrant community of empowered advocates can make a real impact on the policy decisions that will improve our health. With the support of our partners, Read More >
FDA Safety and Innovation Act: A Step Forward for Patients With Rare Diseases
By Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD) The Food and Drug Administration Safety and Innovation Act (FDASIA) includes the most groundbreaking measures for rare disease patients and their families since the Orphan Drug Act of 1983. And, just as the rare disease patient community—with NORD as its unifying voice—played a major role in the Orphan Drug Act, NORD and rare disease patients have taken a leadership role in developing Read More >
Analysis and Impact of PDUFA V
As the House of Representatives voted unanimously to approve legislation to approve the Prescription Drug User Fee Act (PDUFA) V, industry leaders gathered at the 2012 BIO International Convention for a lively discussion on the changes the new legislation, focused on modernizing Food and Drug Administration regulations, will bring to the biotechnology industry. The super session panel discussion was moderated by Steve Usdin, Washington Editor of BioCentury and Co-Host of BioCentury This Week, and included Read More >
We Are BIO
Here’s what the Biotechnology Industry Organization is doing for you. This year, we challenged you to answer the question – What’s Your BIO? On behalf of the Biotechnology Industry Organization (BIO), I’d like to answer that question to illustrate how we advocate for federal, state and global policies to foster continued biotech breakthroughs, innovation and ingenuity. In addition to producing the BIO International Convention, we educate and engage public policy leaders in Washington, in state Read More >
Jim's Corner
Leave a comment
Email This Post
Tags: 2012 BIO International Convention, agricultural biotechnology, agriculture, BIO International Convention, business development, Health Care, International, PDUFA, prescription drugs, public policy, reimbursment, sbir, small business, TDP, Therapeutic Discovery Project
Tags: 2012 BIO International Convention, agricultural biotechnology, agriculture, BIO International Convention, business development, Health Care, International, PDUFA, prescription drugs, public policy, reimbursment, sbir, small business, TDP, Therapeutic Discovery Project
